Etanercept clearance during an in vitro model of continuous venovenous hemofiltration

Blood Purification

Volumn 28, Issue 4, 2009, Pages 348-353

  Fleming, Geoffrey M ^a   Salama, Noha N ^b,d   Eid, Saada K ^c   Cooke, Kenneth R ^c   Mueller, Bruce A ^b  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

Continuous renal replacement therapy; Etanercept; Hemofiltration

Indexed keywords

ETANERCEPT; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYSULFONE;

ARTICLE; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEMOFILTRATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ACRYLIC RESINS; ADSORPTION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATTLE; HEMOFILTRATION; IMMUNOGLOBULIN G; MEMBRANES, ARTIFICIAL; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; POLYMERS; POLYMETHYL METHACRYLATE; RECEPTORS, TUMOR NECROSIS FACTOR; SULFONES;

EID: 69549095669     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232936     Document Type: Article

References (27)

1. Weinberg JM, Bottino CJ, Lindholm J, Buchholz R: Biologic therapy for psoriasis: An update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell targeted therapies efalizumab and alefacept. J Drugs Dermatol 2005; 4: 544-555.
2. Yanik GA, Uberti JP, Ferrara JLM, et al: Soluble tumor necrosis factor receptor: Enbrel (Enbrel - ) for the treatment of idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 89.
3. Cooke KR, Hill GR, Gerbitz A, et al: Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70: 272-279.
4. Cooke KR, Gerbitz A, Crawford JM, et al: LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107: 1581-1589.
5. Yanik G, Hellerstedt B, Custer J, et al: Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 395-400.
6. Sandborn WJ: New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 2005; 5: 10-18.
7. DiCarlo JV, Alexander SR, Agarwal R, Schiffman JD: Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy. J Pediatr Hematol Oncol 2003; 25: 801-805.
8. Kuang D, Verbine A, Ronco C: Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clin Nephrol 2007; 65: 267-284.
9. Böhler J, Donauer J, Keller F: Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidney Int Suppl 1999; 72:S24-S28.
10. Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24: 548-554.
11. Mann H, Melzer H, Al-Bashir A, Xu XQ, Stiller S: Testing protein permeability of dialysis membranes using SDS-PAGE. Int J Artif Organs 2002; 25: 441-446.
12. Langsdorf LJ, Zydney AL: Effect of blood contact on the two transport properties of hemodialysis membranes: A two-layer membrane model. Blood Purif 1994; 12: 292-307.
13. Moachon N, Boullanger C, Fraud S, Vial E, Thomas M, Quash G: Influence of the charge of low molecular weight proteins on their efficacy of filtration and/or adsorption on dialysis membranes with different intrinsic properties. Biomaterials 2002; 23: 651-658.
14. Röckel A, Hertel J, Fiegel P, Abdelhamid S, Danitz N, Walb D: Permeability and second membrane formation of a high flux polysulfone hemofilter. Kidney Int 1986; 30: 429-432.
15. Clark WR, Macias WL, Molitoris BA, Wang NH: Membrane adsorption of - 2-microglobulin: Equilibrium and kinetic characterization. Kidney Int 1994; 46: 1140-1146.
16. Clark WR, Macias WL, Molitoris BA, Wang NH: Plasma protein adsorption to highly permeable hemodialysis membranes. Kidney Int 1995; 48: 481-488.
17. Yekebas EF, Eisenberger CF, Ohnesorge H, et al: Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med 2001; 29: 1423-1430.
18. Cole L, Bellomo R, Davenport P, Tipping P, Ronco C: Cytokine removal during continuous renal replacement therapy: An ex vivo comparison of convection and diffusion. Int J Artif Organs 2004; 27: 388-397. (Pubitemid 38812186)
19. Kellum JA, Dishart MK: Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats. Crit Care 2002; 6: 429-433.
20. Ronco C, Ricci Z, Bellomo R: Importance of increased ultrafiltration volume and impact on mortality: Sepsis and cytokine story and the role of continuous veno-venous haemofiltration. Curr Opin Nephrol Hypertens 2001; 10: 755-761.
21. Ronco C, Inguaggiato P, D'Intini V, et al: The role of extracorporeal therapies in sepsis. J Nephrol 2003; 16:S34-S41.
22. Bonomini M, Fiederling B, Bucciarelli T, Manfrini V, Di Ilio C, Alvertazzi A: A new polymethylmethacrylate membrane for hemodialysis. Int J Artif Org 1996; 19: 232-239.
23. Nakamura AT, Btaiche IF, Pasko DA, Jain JC, Mueller BA: In vitro clearance of trace elements via continuous renal replacement therapy. J Ren Nutr 2004; 14: 214-219.
24. Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA: Trace element removal during in vitro and in vivo continuous hemodialysis. Nephrol Dial Transplant 2007; 22: 2970-2977.
25. Bolton S: Statistics; in Gennaro AR (ed): Remington's Pharmaceutical Sciences. 18th edition. Easton, Mack Publishing, 1990, pp 104-137.
26. De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846-853.
27. Goldstein SL, Somers MJ, Baum MA, et al: Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005; 67: 653-658.